BMS-8

BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1[1].

Product Specifications

CAS Number

[1675201-90-7]

Product Name Alternative

CS-3150; XL-550

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

PD-1/PD-L1

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bms-8.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 83.33 mg/mL (ultrasonic)

Smiles

CC1=C(C=CC=C1C2=CC=CC=C2)COC3=CC=C(C=C3Br)CN4CCCCC4C(O)=O

Molecular Formula

C27H28BrNO3

Molecular Weight

494.42

Precautions

H302, H315, H319

References & Citations

[1]Eun-Hye Kim, et al. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions. Int J Mol Sci. 2020 May 21;21 (10) :3639.|[2]Danfeng Shi, et al. Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship. Front Chem. 2019 Nov 12;7:764.